UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2024

HealthLynked Corp.

(Exact name of registrant as specified in charter)

1265 Creekside Parkway, Suite 302, Naples FL 34108

(Address of principal executive offices)

(800) 928-7144

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act: None.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Operating Officer 

On June 25, 2024, HealthLynked Corp., a Nevada corporation (the “Company”), appointed William Crupi, age 35, as its Chief Operating Officer, effective immediately. Mr. Crupi has served as the Company’s Operations Manager since April 2023. Mr. Crupi previously served as Area Manager for Quigley Eye Specialists and Business Manager at Eye Site of Tampa Bay, both where he managed daily operations of multiple medical facilities, and as an Executive Recruiter at Morisey-Dart Group, where he partnered with clients in identifying qualified candidates for difficult executive roles in the medical device, manufacturing, and engineering fields.

The Company and Mr. Crupi have agreed that Mr. Crupi’s base salary will be $120,000 per year, and that he will be eligible to participate in the benefit plans and programs generally available to the Company’s employees. Mr. Crupi will also receive a 10-year stock option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.081 that shall vest ratably on each of June 25, 2025, June 25, 2026 and June 25, 2027.

There are no arrangements or understandings between Mr. Crupi and any other person pursuant to which he was selected for his position. In addition, there are no family relationships between Mr. Crupi and any directors or executive officers of the Company, and no transactions are required to be reported under Item 404(a) of Regulation S-K between Mr. Crupi and the Company.

Item 7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 of this Current Report on Form 8-K is a press release issued by the Company with regard to Mr. Crupi’s appointment as Chief Operating Officer. The press release shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

Item 9.01.  Financial Statements and Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.